Ignite Creation Date:
2024-05-06 @ 5:42 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05403710
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2022-05-16
Brief Title:
Botulinum Toxin Therapy in Hidradenitis Suppurativa
Sponsor:
University of Massachusetts Worcester
Organization:
University of Massachusetts Worcester
Study Overview
Official Title:
Targeting Nociceptors in Hidradenitis Suppurativa
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HS
Brief Summary:
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa HS In this study the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation
Detailed Description:
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release The investigators will collect punch biopsies of lesional skin from HS patients before and 1-2 months after botulinum toxin treatment 50U per axilla in 10 injections of 01mL then perform flow cytometric transcriptomic and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 7K08AR080844-02 | NIH | None | httpsreporternihgovquickSearch7K08AR080844-02 |